PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer SUMMIT 2021

5-6 February 2021 Virtual Conference

N. Poster

Poster title

Applicant name

Status


P-001	Surgery versus Sorafenib in case of BCLC-C hepatocellular carcinoma: an Italian weighted study	Simone Famularo	Received

P-002	Current Trends of Hepatocellular Carcinoma Characteristics in Greece	Georgios Markakis	Received

P-003	Patterns of response to atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) from the Phase 1b GO30140 study	Stacey Stein	Received

P-004	Association between serum magnesium concentration and hepatocellular carcinoma in cirrhotic patients	Simona Parisse	Received

P-005	The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database	Francesca Carissimi	Received

P-006	Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids	Mikel Ruiz de Gauna	Received

P-008	Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy	Haochen Wang	Received

P-009	Hepatocellular carcinoma prognostic scores: filling the gap?	Michele Campigotto	Received

P-010	A real-world evaluation of baseline characteristics, treatment patterns, and survival outcomes in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein levels receiving second-line therapy in the United States	Rajiv Ulpe	Received

P-011	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target?	Alberto Zanetto	Received

P-012	Comparison of Sorafenib and Lenvatinib as first line therapy in Unresectable Hepatocarcinoma: a multi-center propensity score matching analysis	Margherita Rimini	Received

P-013	chronic hepatitis b under tenofovir or entecavir: performance of the page-b score to predict hepatocellular carcinoma	Daniela Falcão	Received

P-014	Diagnosing hepatocellular carcinoma are we getting it right first time?	Emma Saunsbury	Received

P-015	Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib	Piero Colombatto	Received

P-016	Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand	Pattapon Kunadirek	Received

P-017	Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis	Pattapon Kunadirek	Received

P-018	Association between postoperative early recurrence of hepatocellular carcinoma and the expression pattern of circulating tumor cells in peripheral blood sample: a preliminary study.	Cristina Ciulli	Received

P-019	Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma	Filippo Pelizzaro	Received

P-020	Establishment of 3D-organoids from cryopreserved cancer tissues	Colin Rae	Received

P-021	Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients	Filippo Pelizzaro	Received

P-022	Impact of hospital volume on hepatocellular carcinoma survival in Italy	Filippo Pelizzaro	Received

P-023	Sarcomatoid hepatocellular carcinoma has distinct immunologic hallmarks from ordinary hepatocellular carcinoma	Ryo Morisue	Received

P-024	Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study	OPEN Health	Received

P-025	Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a cohort study in Taiwan	Ching-Sheng Hsu	Received

P-026	Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma	OPEN Health	Received

P-027	Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma.	Petros Fessas	Received

P-028	Are undetected stones in the common biliary duct one of the causes of abscesses and bilomas development after percutaneous thermal ablation procedures?	Letizia Veronese	Received

P-029	Different modalities in management of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients with or without hepatocellular Carcinoma	Mohamed Abdel-Samiee	Received

P-030	Copper chelators old drugs for new uses in the treatment of hepatocellular carcinoma	Silvano Junior Santini	Received

P-031	Diagnostic accuracy of a-fetoprotein (AFP), protein induced by vitamin K absence (PIVKA-II) and fibrogen like protein-2 (FGL-2) for HCC diagnosis among patients with liver cirrhosis	antonia syriha	Received

P-032	NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice	MACARENA HERRANZ ITÚRBIDE	Received

P-033	Development of ex vivo and in vivo tissue models of hepatocellular carcinoma and utility for immunotherapy investigations	Amy Collins	Received

P-034	Methylated Septin 9 (mSEPT9) as a biomarker for hepatocellular carcinoma. Results from University Hospital Coventry and Warwickshire NHS Trust, UK	Ayman Bannaga	Received

P-036	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.	David Pinato	Received

P-037	PNPLA3 and Notch3 gene polymorphisms as risk factors for alcoholic cirrhosis development and its progression to hepatocellular carcinoma	Anna Mrzljak	Received

P-038	Urinary volatile organic compounds characterization in hepatocellular carcinoma pilot study	Ayman Bannaga	Received

P-039	Comparison of incidence and mortality risks due to acute kidney injury in hepatocellular carcinoma patients after liver resection, ablation, and transarterial chemoembolization: Meta-analysis of cohort studies	Boby Pratama Putra	Received

P-040	Predictive value of biomarkers a-fetoprotein (AFP) and fibrogen like protein-2 (FGL-2) for HCC among patients with liver cirrhosis	antonia syriha	Received

P-041	Transarterial chemoembolization: Predictors of liver function deterioration prior to hepatocellular carcinoma refractoriness	Joel Ferreira-Silva	Received

P-042	Two birds one stone: a case of synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma	Catarina Félix	Received

P-043	Virtual biopsy for diagnosis of steatohepatitis and chemotherapy-associated liver injuries. A combined radiomic and clinical model.	Guido Costa	Received

P-045	Hepatic and extrahepatic colorectal metastases have discordant responses to systemic therapy. Pathology data from patients undergoing simultaneous resection of multiple tumor sites	Pio Corleone	Received

P-046	A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.	Thomas Talbot	Received

P-047	Hsa-miR-21-5p disturbs the liver metabolic network in patients with NAFLD and is increased in NASH-associated HCC, contributing to hepatocarcinogenesis in mice	Pedro Rodrigues	Received

P-048	Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC. A single center retrospective case control study.	Bianca Rocco	Received

P-049	Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out	Lorenzo Mulazzani	Received

P-050	Chronic disruption of the late cholesterol synthesis leads to female-prevalent liver cancer	damjana rozman	Received

P-052	Human antigen R (HuR) SUMOylation is a fine-tuner of hepatocellular carcinoma (HCC) progression via the modulation of key mitochondrial mRNAs	Sofia Lachiondo-Ortega	Received

P-053	GALAD Score shows improved detection of early stage hepatocellular carcinoma in a Caucasian cohort of chronic Hepatitis B and C	Clemens Schotten	Received

P-054	Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study.	Lorena Carballo-Folgoso	Received

P-055	Treatment of the chemotherapy induced hepatotoxicity	Mariia Zharova	Received

P-056	Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases	André L. Simão	Received

P-057	Hepatocellular Carcinoma Surveillance in Cirrhotic patients.	Shreyashee Sengupta	Received

P-058	Dynamic risk profile of hepatocellular carcinoma recurrence after curative intent liver resection	Tommy Ivanics	Received

P-059	Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma	Darko Castven	Received

P-060	Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients	Anthony Tan	Received

P-061	Circular RNA expression is modulated by RNA-binding proteins in hepatocellular carcinoma	Rok Razpotnik	Received

P-062	The impact of ultrasonographic blind spots for detecting early-stage hepatocellular carcinoma during surveillance	HA IL KIM	Received

P-063	Prognostic factors and post-treatment survival in patients enrolled onto second-line trials for unresectable hepatocellular carcinoma after sorafenib: a multicentre Italian cohort study	Nicola Personeni	Received

P-064	FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling	Giulia Cristinziano	Received

P-065	Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC)	Regina Wong	Received

P-066	The combination of alcohol and metabolic syndrome is a fast track to hepatic tumorigenesis	Raquel Benedé-Ubieto	Received

P-067	Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study	Linda Skibsted Kornerup	Received

P-068	Usefulness of circulating tumor cells in the management of patients with hepatocellular carcinoma	Elena Vargas Accarino	Received

P-069	Prognostic value of metabolic imaging data of C-choline PET/CT in patients undergoing hepatectomy for hepatocellular carcinoma	Jacopo Galvanin	Received

P-070	First real-life experience with atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma	Martin Schnlein	Received

P-071	Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells	Alessandra Gentilini	Received

P-072	Alteration of miRNA content in extracellular vesicles in Sorafenib-treated liver cancer cells. miRNA prognostic value in plasma from patients with advanced HCC treated with Sorafenib	Patricia de la Cruz-Ojeda	Received

P-073	Virological and oncological factors of HCC recurrence after liver trasplantation in a single transplant center	Martina Gambato	Received

P-074	Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma	Claudia Campani	Received

P-075	Tumor Burden Score: a novel tool to predict immune-related liver injury during immunotherapy for hepatocellular carcinoma	Antonio DAlessio	Received

P-076	Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation	Arndt Vogel	Received

P-077	PRPF8 regulates FAK/AKT pathway via fibronectin 1 splicing modulation to promote hepatocellular carcinoma aggressiveness	Juan Luis López-Cánovas	Received

P-078	Retrospective analysis of one-center experience in diagnosis and treatment of liver cancer	Mariia Zharova	Received

P-079	Analysis of risk factors associated with hepatocellular carcinoma development in patients with hepatitis B virus infection	Christos Triantos	Received

P-081	Validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow	Chris Curran	Received

P-082	In vivo quantification of micro-balloon interventions (MBI) advantage. Cohort, retrospective, bi-centric study of DEB-TACE vs b-TACE and SIRT vs b-SIRT	Claudio Trobiani	Received

P-083	Comparison of Liver Transplant Criteria for Hepatocellular Carcinoma	Volkan &304;nce	Received

P-084	LDH as early prognostic markers for response in advanced hepatocellular carcinoma treated with Nivolumab	radu Pompilia	Received

P-085	DNA Methyltransferases as Potential Biomarkers for Egyptian Patients with HCV Related Hepatocellular Carcinoma	Mohamed Abdel-Samiee	Received

P-086	Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma	Jimmy A. Daza Barragan	Received

P-087	Se and Zn supplements attenuates HCC among recovered Hepatitis C Obese population in Middle Belt Nigeria.	OLAJUYIN OLALEYE	Received

P-088	CAMD score predicts the risk of hepatocellular carcinoma in Tunisian patients with chronic hepatitis B on antiviral therapy	Myriam Ayari	Received

P-089	Centrality of Estrogen Receptor 1 in Modulating Hepatocellular Carcinoma Progression through Wnt signaling	Elisa Pasini	Received

P-090	Hepatoprotective effects of pirfenidone in early stages of hepatocellular carcinoma	Jorge Silva-Gomez	Received

P-091	Real-world experience of hepatocellular carcinoma patients after sorafenib treatment: eligibility to subsequent lines and prognostic factors.	Leonardo Gomes da Fonseca	Received

P-092	Hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors	Nicola Personeni	Received

P-093	Identification of a prognostic 3-protein score of childhood liver cancer by proteomic profiling	Juan Carrillo	Received

P-094	Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome.	Maria Guarino	Received

P-095	Title: Quantification of extracellular matrix features and its implications in hepatocellular carcinoma patients after curative liver resection	Kaiwen Huang	Received

P-096	Enhanced mitochondrial activity and immunometabolic reprogramming, by silencing Methylation Controlled J protein (MCJ), accelerates liver tumorigenesis in a hepatocellular carcinoma (HCC) mice model	Naroa Goikoetxea-Usandizaga	Received

P-097	Absence of a complete response after two trans-arterial chemo-embolizations during liver transplantation waiting list: should we persist or change?	Edoardo Poli	Received

P-098	Prediction of early recurrence of hepatocellular carcinoma after resection: international validation of the ERASL risk models	Berend Beumer	Received

P-099	Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment	Thorben Frndt	Received

P-100	PD-1 expression, polymorphisms in PDCD1 and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD).	HELEN REEVES	Received

P-101	Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?	Ciro Celsa	Received

P-102	Circulating miR 373 but not miR 210 as a new promising preoperative predictor of response to superive transarterial chemoembolization bridging therapy in Egyptian patients with hepatocellular carcinoma on top of hepatitis C virus infection	Omneya AbdelKarem	Received

P-103	Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients	Berend Beumer	Received

P-105	Endothelial Angiopoietin-2 overexpression in explanted HCCs identifies subjects at high risk of recurrence after liver transplant	Alessandra Pivetti	Received

P-106	Role of LI-RADS indeterminate observations in the prediction of HCC occurrence after direct antiviral therapy for hepatitis C virus infection.	Francesco Matteini	Received

P-107	lncRNA-H19 as a marker of liver disease progression: Hepatocellular Carcinoma	Ángela Rojas	Received

P-108	Nanobody-targeted liposomes for photodynamic therapy of Cholangiocarcinoma	Bárbara Mesquita	Received

P-109	Effectiveness of hepatocellular carcinoma treatments with curative intent: a nationwide study	Frederik Kraglund	Received

P-110	Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) in Italy.	Monica Cucco	Received

P-111	An unexpected side effect of lenvatinib in patients treated for advanced hepatocellular carcinoma: increased hemoglobin level and erythrocytosis	Alina Pascale	Received

P-112	Are Radiology-based endpoints robust surrogate outcomes of overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization?	Ciro Celsa	Received

P-113	Vimentin expression in hepatocellular carcinoma relates with progenitor cells and epithelial-mesenchymal transition carcinogenesis	Joana Espírito Santo	Received

P-114	Inducing tissue-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma	Nekisa Zakeri	Received

P-115	Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment	Gemma Iserte	Received

P-116	A CIRCULATING microRNAs SIGNATURE IDENTIFIES DAA-TREATED HCV-RELATED CIRRHOSIS PATIENTS AT HIGH RISK TO DEVELOP HCC	Massimo Levrero	Received

P-117	Cancer-associated pathways modulated by O-GlcNAc transferase and Enhancer of Zeste homolog 2 in hepatocellular carcinoma	Massimo Levrero	Received

P-118	Assessment of the impact of COVID-19 pandemic on Liver Cancer Management (CERO-19)	Sergio Munoz-Martínez	Received

P-119	Modified Page B Score Performance in Predicting HCC Risk in patients with chronic hepatitis B on antiviral therapy.	Fatma Ben Farhat	Received

P-120	CIRCULATING microRNAs PREDICT HEPATOCELLULAR CARCINOMA IN NUC-SUPPRESSED HBV CIRRHOTIC PATIENTS	Massimo Levrero	Received

P-121	Liver decompensation as late complication in HCC patients with long term response following ive internal radiation therapy.	Diederick van Doorn	Received

P-122	Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma	Nouha Trad	Received

P-123	Safety and benefit of the combination of regorafenib and nivolumab in patients with hepatocellular carcinoma (HCC) in progression beyond two lines of oral chemotherapy	Ben merabet Yasmina	Received

P-124	Incidence of Hepatocellular Carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A Systematic Review Meta-Analysis and Meta-Regression	Marco Sanduzzi Zamparelli	Received

P-125	Performance of ten non-invasive liver function tests in predicting one-year mortality in patients with hepatocellular carcinoma	Nouha Trad	Received

P-126	Impact of Hepatocellular Carcinoma screening in patients with Non-Achoholic Fatty Liver Disease and survival analyzis: a Brazilian Cross-Section Study	Regiane Saraiva de Souza Melo Alencar	Received

P-127	Whole-transcriptome profiling of biopsies from unresectable intrahepatic cholangiocarcinoma (iCCA) reveals a prognostic signature with treatment implications.	Massimiliano Salati	Received

P-128	Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or waiting and see strategy?	Alessandro Vitale	Received

P-129	PSMA PET/CT imaging has equivalent performance to MRI for characterising hepatocellular carcinoma	Veronica Wong	Received

P-130	Stellate cell activation in liver cancer treatment	Xiaowen Liang	Received

P-131	Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis	Antoine Hollebecque	Received

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer SUMMIT 2021

5-6 February 2021 Virtual Conference

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 11/01/2021 TO 05/02/2022

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access